Bristol Myers reports Krazati confirmatory trial fails in colorectal cancer

Bristol Myers Squibb disclosed that the confirmatory study of its investigational drug Krazati in combination with an EGFR inhibitor did not achieve its primary efficacy endpoints in patients with colorectal cancer.

The trial was intended to verify earlier signals of activity and to support further development of Krazati for this indication. The lack of statistical significance means the company will not pursue regulatory approval for colorectal cancer at this time.

The setback highlights the challenges of extending targeted therapies to colorectal tumors and may shift the company's focus toward other indications where Krazati has shown more promise.